

IN THE CLAIMS

Please amend the claims as follows:

Claims 1- 10 (Cancelled).

Claim 11 (New): A method for the treatment of psoriasis and inflammatory processes of the skin and/or joints of mammals and humans comprising:

administering to a patient in need thereof a composition comprising an effective dose of a substance of the porphyrin synthesis or pharmacologically compatible salt thereof; and  
irradiating with light having a wavelength of 400 to 700 nm.

Claim 12 (New): The method of Claim 11, wherein the composition further comprises a salicylate.

Claim 13 (New): The method of Claim 12, wherein the composition additionally comprises an antioxidant.

Claim 14 (New): The method of Claim 11, wherein the substance of the porphyrin synthesis is 5-aminolevulinic acid.

Claim 15 (New): The method of Claim 12, wherein the salicylate is at least one selected from the group consisting of acetylsalicylic acid, salicylic acid, sodium salicylate, methyl salicylate and hydroxyethyl salicylate.

Claim 16 (New): The method of Claim 15, wherein the salicylate is acetylsalicylic acid.

Claim 17 (New): The method of Claim 13, wherein the antioxidant is at least one selected from the group consisting of ascorbic acid, isoascorbic acid, tocopherol, gluconic acid, a carotenoid and a pharmacologically compatible salt of any of these.

Claim 18 (New): The method of Claim 17, wherein the antioxidant is ascorbic acid.

Claim 19 (New): The method of Claim 11, wherein the light has a wavelength of 520 to 580 nm.

Claim 20 (New): The method of Claim 19, wherein the light has a wavelength of approximately 545 nm.

Claim 21 (New): The method of Claim 11, wherein the psoriasis and inflammatory processes of the skin and/or joints of mammals and humans comprise at least one selected from the group consisting of arthritis, plaque psoriasis, arthritic psoriasis and neuropathy.

Claim 22 (New): The method of Claim 21, wherein the neuropathy is carpal tunnel syndrome or Bekterev's disease.

Claim 23 (New): A pharmaceutical composition comprising a substance of the porphyrin synthesis or pharmacologically compatible salts thereof in combination with a salicylate, wherein the pharmaceutical composition is for the phototherapy of psoriasis and inflammatory processes of the skin and/or joints of mammals and humans.

Claim 24 (New): The pharmaceutical composition of Claim 23, wherein the substance of porphyrin synthesis is 5-aminolevulinic acid.

Claim 25 (New): The pharmaceutical composition of Claim 23, wherein the salicylate is at least one selected from the group consisting of acetylsalicylic acid, salicylic acid, sodium salicylate, methyl salicylate and hydroxyethyl salicylate.

Claim 26 (New): The pharmaceutical composition of Claim 25, wherein the salicylate is acetylsalicylic acid.

Claim 27 (New): The pharmaceutical composition of Claim 23, additionally comprising an antioxidant.

Claim 28 (New): The pharmaceutical composition of Claim 27, wherein the antioxidant is at least one selected from the group consisting of ascorbic acid, isoascorbic acid, tocopherol, gluconic acid, a carotenoid and a pharmacologically compatible salt of any of these.

Claim 29 (New): The pharmaceutical composition of Claim 28, wherein the antioxidant is ascorbic acid or a pharmacologically compatible salt thereof.

Claim 30 (New): A pharmaceutical composition comprising:

5-aminolevulinic acid;  
acetylsalicylic acid; and  
ascorbic acid; wherein

the acetylsalicylic acid is in a weight ratio of 3:1 relative to the 5-aminolevulinic acid and the ascorbic acid is in a weight ratio of 2:1 relative to the 5-aminolevulinic acid; and the pharmaceutical composition is for the phototherapy of psoriasis and inflammatory processes of the skin and/or joints of mammals and humans.